Research programme: cathepsin K inhibitors - Celera Group/Merck

Drug Profile

Research programme: cathepsin K inhibitors - Celera Group/Merck

Alternative Names: 39n; CRA-013783; L-006235; L-235

Latest Information Update: 29 Aug 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Celera Group; Merck & Co
  • Developer Merck & Co
  • Class Amides; Nitriles; Piperazines; Small molecules
  • Mechanism of Action Cathepsin K inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Bone cancer; Osteoporosis

Most Recent Events

  • 29 Aug 2011 No development reported - Preclinical for Osteoporosis in Canada (PO)
  • 29 Aug 2011 No development reported - Preclinical for Osteoporosis in USA (PO)
  • 29 Aug 2011 No development reported for Bone cancer in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top